Clinical Trials

52 results for Bladder Cancer


Molecular Correlates of Sensitivity and Resistance to Therapy in Genitourinary Malignancy

  • Condition: Healthy Control, Localized Urothelial Carcinoma of the Renal Pelvis and Ureter, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Recurrent Bl
  • Intervention: Other: Cytology Specimen Collection Procedure, Other: Laboratory Biomarker Analysis
  • Study ID: NCT01050504
View Trial

A Randomized Phase II Trial Evaluating an Organ-conserving Strategy With Radiotherapy + CDDP + Gemcitabine vs Radiotherapy + CDDP in Muscle-infiltrative Bladder Cancer

  • Condition: Infiltrating Bladder Urothelial Carcinoma
  • Intervention: Other: Radiation + cisplatin, Other: Radiation + cisplatin + gemcitabine
  • Study ID: NCT01495676
View Trial

Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer

  • Condition: Bladder Cancer
  • Intervention: Drug: Pembrolizumab, Drug: Cisplatin, Radiation: Radiotherapy
  • Study ID: NCT02662062
View Trial

Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging

  • Condition: Muscle-invasive Bladder Cancer
  • Intervention: Other: Whole-body FDG PET-CT
  • Study ID: NCT02462239
View Trial

Phase I Study of Hypofractionated Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) in the Treatment of Advanced Bladder Cancer

  • Condition: Invasive Bladder Cancer
  • Intervention: Drug: Pembrolizumab, Radiation: Radiotherapy
  • Study ID: NCT02560636
View Trial

MDSC Clinical Assay for Cancer Detection and Monitoring in Bladder Carcinoma

  • Condition: No Evidence of Disease, Stage II Bladder Cancer, Stage III Bladder Cancer, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer
  • Intervention: Other: Cytology Specimen Collection Procedure, Other: Laboratory Biomarker Analysis
  • Study ID: NCT02735512
View Trial

Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial)

  • Condition: Cholangiocarcinoma, Gall Bladder Carcinoma
  • Intervention: Drug: Gemcitabine, Drug: Cisplatin, Other: Observation
  • Study ID: NCT02170090
View Trial

Prospective Randomized Trial of Adjuvant Radiotherapy Following Surgery and Chemotherapy in Muscle Invasive Transitional Cell Carcinoma of Urinary Bladder

  • Condition: Bladder Cancer, Urothelial Carcinoma Bladder
  • Intervention: Radiation: Adjuvant RT
  • Study ID: NCT02951325
View Trial

A Phase II Study of the Anti-PD-L1 Antibody MPDL3280A in Subjects With Non-metastatic Transitional Cell Carcinoma of the Bladder

  • Condition: Carcinoma, Transitional Cell
  • Intervention: Drug: MPDL3280A Dose Level 1, Drug: MPDL3280A Dose Level 2, Drug: MPDL3280A Dose Level 3
  • Study ID: NCT02451423
View Trial

Lymphadenectomy in Urothelial Carcinoma in the Renal Pelvis and Ureter

  • Condition: Ureteral Neoplasms [C12.758.820.875]
  • Intervention: Procedure: Lymphadenectomy in conjugation with nephroureterectomy, Procedure: Nephroureterectomy without lymphadenectomy
  • Study ID: NCT02607709
View Trial

A Phase 1 Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

  • Condition: Malignant Reproductive System Neoplasm, Malignant Urinary System Neoplasm, Metastatic Urethral Neoplasm, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Progressive Neoplastic Disease, Recurrent Bladder Carcinoma, Recurrent Urethra C
  • Intervention: Drug: Cabozantinib S-malate, Biological: Ipilimumab, Other: Laboratory Biomarker Analysis, Biological: Nivolumab
  • Study ID: NCT02496208
View Trial

A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma

  • Condition: Cancer
  • Intervention: Drug: GSK3326595 Capsules
  • Study ID: NCT02783300
View Trial

Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer of the Bladder and Kidney

  • Condition: Urothelial Cancer, Cancer, Bladder Neoplasms, Urinary Bladder Cancer
  • Study ID: NCT00872495
View Trial

Atezolizumab in Combination With Gemcitabine and Cisplatin As First-Line Treatment in Metastatic Urothelial Cancer: A Multicenter Randomized Phase II Study of Two Alternative Dosing Schedules

  • Condition: Urothelial Carcinoma, Locally Advanced, Unresectable
  • Intervention: Drug: Atezolizumab, Drug: Gemcitabine, Drug: Cisplatin
  • Study ID: NCT03093922
View Trial

A Phase 1b, Open-label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of NKTR 214 and Anti-PD-L1 (Atezolizumab) in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer or Metastatic Non-Small Cell Lung Cancer

  • Condition: Non-Small Cell Lung Cancer, Urinary Bladder Neoplasms, Neoplasm Metastasis
  • Intervention: Drug: Combination of NKTR-214 + atezolizumab
  • Study ID: NCT03138889
View Trial

Intervention of Advanced or Metastatic Urothelial Bladder Cancer by 4SCAR-T Cell Therapies

  • Condition: Bladder Cancer, Urothelial Carcinoma Bladder
  • Intervention: Genetic: 4SCAR-PSMA, Genetic: 4SCAR-FRa
  • Study ID: NCT03185468
View Trial

A Phase II Open Label Single Arm Study of Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer (NEXT)

  • Condition: Bladder Cancer
  • Intervention: Drug: Nivolumab
  • Study ID: NCT03171025
View Trial

Four Cycles of Cisplatin-Based Chemotherapy in Metastatic Urothelial Carcinoma Compared to Six Cycles: Randomized Phase III Trial - FOCUS Study -

  • Condition: Bladder Cancer, Ureter Cancer, Urethral Cancer, Transitional Cell Carcinoma
  • Intervention: Drug: Treatment duration of cisplatin based chemotherapy
  • Study ID: NCT03296306
View Trial

Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation

  • Condition: Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma
  • Intervention: Other: Clinical Observation, Other: Laboratory Biomarker Analysis, Biological: Pembrolizumab, Other: Pharmacological Study, Other: Quality-of-Life Assessment, Other: Questionnaire Administration
  • Study ID: NCT03244384
View Trial

Randomized Phase II Study of Neoadjuvant Nivolumab With and Without Urelumab in Patients With Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder

  • Condition: Urothelial Carcinoma, Bladder Cancer
  • Intervention: Drug: Nivolumab in combination with Urelumab, Drug: Nivolumab monotherapy
  • Study ID: NCT02845323
View Trial

A Phase I Single-Arm Study of the Combination of Durvalumab (MEDI4736) and Vicinium (Oportuzumab Monatox, VB4-845) in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With BCG

  • Condition: Urinary Bladder Neoplasms
  • Intervention: Drug: Durvalumab, Drug: Vicinium
  • Study ID: NCT03258593
View Trial

Phase 2 Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

  • Condition: Metastatic Urothelial Cancer
  • Intervention: Drug: Olaparib
  • Study ID: NCT03448718
View Trial

A Pilot Study to Evaluate the Safety of Neoadjuvant Nivolumab Alone or in Combination With Ipilimumab for Cisplatin-Ineligible Patients With Muscle Invasive Bladder Cancer (CA209-9DJ)

  • Condition: Bladder Cancer
  • Intervention: Drug: Nivolumab, Drug: Ipilimumab, Procedure: Radical cystectomy
  • Study ID: NCT03520491
View Trial

A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients With Muscle-Invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations

  • Condition: Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma
  • Intervention: Drug: Gemcitabine Hydrochloride, Drug: Cisplatin, Biological: Pegfilgrastim, Procedure: Conventional Surgery, Procedure: Radical Cystectomy, Other: Chemoradiotherapy
  • Study ID: NCT03609216
View Trial

A Phase 2 Study of Sitravatinib in Combination With Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma

  • Condition: Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Urethra
  • Intervention: Drug: Sitravatinib, Drug: Nivolumab
  • Study ID: NCT03606174
View Trial

Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers

  • Condition: Non-metastatic Muscle Invasive Bladder Cancer
  • Intervention: Drug: Avelumab, Procedure: cystectomy, Combination Product: CG, Combination Product: DD-MVAC, Combination Product: PG
  • Study ID: NCT03674424
View Trial

Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (PemCab)

  • Condition: Metastatic Urothelial Carcinoma, Bladder Cancer
  • Intervention: Drug: Cabozantinib, Drug: Pembrolizumab
  • Study ID: NCT03534804
View Trial

Neoadjuvant Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing

  • Condition: Bladder Cancer
  • Intervention: Drug: Nivolumab, Drug: Gemcitabine, Drug: Cisplatin
  • Study ID: NCT03558087
View Trial

Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer (Study SWOG/NRG 1806)

  • Condition: Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage III Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
  • Intervention: Drug: Atezolizumab, Drug: Cisplatin, Drug: Fluorouracil, Drug: Gemcitabine, Drug: Mitomycin, Other: Quality-of-Life Assessment, Radiation: Radiation Therapy, Other: Survey Administration
  • Study ID: NCT03775265
View Trial

Pilot Study of Celecoxib Combined With Gemcitabine and Cisplatin for Neoadjuvant Treatment of Localized, Muscle-Invasive Bladder Cancer

  • Condition: Bladder Cancer
  • Intervention: Drug: Celecoxib, Drug: Gemcitabine, Drug: Cisplatin
  • Study ID: NCT02885974
View Trial

A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy Alone Versus Neoadjuvant Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle-

  • Condition: Bladder Cancer, Muscle-Invasive Bladder Cancer, BMS-986205
  • Intervention: Biological: Nivolumab, Drug: BMS-986205, Drug: Gemcitabine, Drug: Cisplatin, Drug: BMS-986205 Placebo
  • Study ID: NCT03661320
View Trial

Gemcitabine-cisplatin Plus Avelumab or Gemcitabine-cisplatin as First-line Treatment of Patients With Locally Advanced or Metastatic Urothelial Bladder Carcinoma (GCISAVE)

  • Condition: Bladder Carcinoma
  • Intervention: Drug: Avelumab, Drug: GC
  • Study ID: NCT03324282
View Trial

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

  • Condition: Acinar Cell Carcinoma, Adrenal Cortex Carcinoma, Adrenal Gland Pheochromocytoma, Anal Canal Neuroendocrine Carcinoma, Anal Canal Undifferentiated Carcinoma, Appendix Mucinous Adenocarcinoma, Bladder Adenocarcinoma, Bronchioloalveolar Carcinoma, Ce
  • Intervention: Procedure: Biospecimen Collection, Biological: Ipilimumab, Biological: Nivolumab
  • Study ID: NCT02834013
View Trial

A Prospective, Single Arm, Multicenter, Phase II-Trial to Assess Safety and Efficacy of Preoperative RAdiation Therapy Before Radical CystEctomy Combined With ImmunoTherapy in Locally Advanced Urothelial Carcinoma of the Bladder

  • Condition: Urinary Bladder Cancer
  • Intervention: Drug: Nivolumab, Radiation: Radiation therapy of the pelvis, Procedure: Radical cystectomy with standardized pelvic lymphadenectomy
  • Study ID: NCT03529890
View Trial

A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients With Mus

  • Condition: Muscle Invasive Bladder Cancer
  • Intervention: Drug: Durvalumab, Drug: Cisplatin, Drug: Gemcitabine
  • Study ID: NCT03732677
View Trial

A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial C

  • Condition: Urothelial Carcinoma
  • Intervention: Biological: Pembrolizumab, Drug: Lenvatinib, Drug: Placebo for lenvatinib
  • Study ID: NCT03898180
View Trial

Phase II Trial of Neutron Radiotherapy With Concurrent Checkpoint Inhibitor Immunotherapy (Pembrolizumab) in Patients With Advanced Urothelial Carcinoma

  • Condition: Urothelial Carcinoma
  • Intervention: Other: Laboratory Biomarker Analysis, Biological: Pembrolizumab, Radiation: Radiation Therapy
  • Study ID: NCT03486197
View Trial

A Pilot Study of Tazemetostat and MK-3475 (Pembrolizumab) in Advanced Urothelial Carcinoma

  • Condition: Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, PD-L1 Positive, Stage III Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIB Bladder
  • Intervention: Biological: Pembrolizumab, Drug: Tazemetostat
  • Study ID: NCT03854474
View Trial

A Phase II Trial to Evaluate Combination Therapy With Pemetrexed and Avelumab in Previously Treated Patients With MTAP-Deficient Advanced Urothelial Cancer

  • Condition: Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation, Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Infiltrating Bladder Urothelial Carcinoma,
  • Intervention: Drug: Avelumab, Drug: Pemetrexed
  • Study ID: NCT03744793
View Trial

Neoadjuvant Chemotherapy Versus Surgery Alone in Patients With High-Grade Upper Tract Urothelial Carcinoma

  • Condition: High-Grade Upper Tract Urothelial Carcinoma
  • Intervention: Procedure: Radical nephroureterectomy, Procedure: Distal ureterectomy, Drug: Neoadjuvant Chemotherapy
  • Study ID: NCT02876861
View Trial

A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy Versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-

  • Condition: Urinary Bladder Cancer, Muscle-invasive
  • Intervention: Drug: Pembrolizumab, Drug: Gemcitabine, Drug: Cisplatin, Procedure: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]), Drug: Placebo
  • Study ID: NCT03924856
View Trial

A Window-of-opportunity Trial of Abemaciclib Followed by Radical Cystectomy in Patients With Platinum-ineligible Urothelial Carcinoma to Evaluate CDK4/6-dependent Phosphorylation of Pocket Proteins and Clonal Evolution Dynamics

  • Condition: Bladder Cancer
  • Intervention: Drug: Abemaciclib
  • Study ID: NCT03837821
View Trial

A Phase 1b-2 Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study

  • Condition: Urinary Bladder Cancer, Invasive Bladder Cancer
  • Intervention: Combination Product: nivolumab 480mg, Combination Product: nivolumab 3mg/kg, ipilimumab 1mg/kg, Combination Product: nivolumab 1mg/kg, ipilimumab 3mg/kg
  • Study ID: NCT03844256
View Trial

A Pilot Study of 18Fluorine-Fluciclovine Positron Emission Tomography/Computed Tomography for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy

  • Condition: Bladder Cancer, Urothelial Carcinoma
  • Intervention: Drug: 18F-fluciclovine, Device: PET/CT
  • Study ID: NCT04018053
View Trial

A Feasibility Study of Durvalumab (MEDI4736) Alone or in Combination With Oleclumab (MEDI9447) as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)

  • Condition: Muscle Invasive Bladder Cancer
  • Intervention: Drug: Durvalumab, Drug: Oleclumab
  • Study ID: NCT03773666
View Trial

A Randomized Phase II Trial Assessing Trimodality Therapy With or Without Adjuvant Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer

  • Condition: Bladder Cancer
  • Intervention: Drug: Durvalumab
  • Study ID: NCT03768570
View Trial

Phase II Study of Avelumab in Combination With AXL Inhibitor AVB-S6-500 in Patients With Advanced Urothelial Carcinoma

  • Condition: Urothelial Carcinoma
  • Intervention: Drug: Avelumab, Drug: AVB-S6-500
  • Study ID: NCT04004442
View Trial

A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Participants With Muscle-invasive Bladder Cancer (MIBC) (KEY

  • Condition: Urinary Bladder Neoplasms
  • Intervention: Drug: Pembrolizumab, Radiation: Conventional Radiotherapy (Bladder only), Radiation: Conventional Radiotherapy (Bladder and pelvic nodes), Radiation: Hypofractionated Radiotherapy (Bladder only), Drug: Cisplatin, Drug: Fluorouracil (5-FU), Drug: Mitomycin C (MMC), Drug: Gemcitabine, Drug: Placebo to Pembrolizumab
  • Study ID: NCT04241185
View Trial

Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)

  • Condition: Upper Tract Urothelial Carcinomas, Urothelial Bladder Cancer
  • Intervention: Drug: Infigratinib, Drug: Placebo
  • Study ID: NCT04197986
View Trial

An Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without Chemotherapy, Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

  • Condition: Urothelial Cancer
  • Intervention: Drug: Enfortumab vedotin, Drug: Pembrolizumab, Drug: Cisplatin, Drug: Carboplatin, Drug: Gemcitabine
  • Study ID: NCT04223856
View Trial